Please login to the form below
Viking Therapeutics
This page shows the latest Viking Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Gilead lead NASH drug flunks phase 3 test
Nevertheless, William Blair thinks the setback could prompt Gilead to seek out other licensing candidates to expand it liver disease pipeline, and they think one possible candidate could be Viking
Latest news
-
Roche enters NASH race with deal to buy Jecure
cutting a deal to acquire US start-up Jecure Therapeutics. ... Other competition is coming from pharma heavyweights Novartis and Pfizer, which recently joined forces to test three drugs in combination, and other clinical-stage player such as Allergan,
-
Viking throws down gauntlet in NASH battle
Impressive data in a phase 2 trial caused shares in Viking Therapeutics to almost double yesterday as investors got excited about another candidate for non-alcoholic steatohepatitis (NASH). ... Viking’s VK2809 – a thyroid hormone receptor beta
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Pharma deals during May 2014
The acquisition for up to $658m (a 59 per cent premium on the pre-bid share price) of the US company, Chelsea Therapeutics, achieves both those goals. ... As a footnote, Ligand this month licensed to what appears to be a new company called Viking
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
-
Healthcare Account Director
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Medical Editor
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Nucleus Global announces a trio of promotions
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- Pfizer introduces new logo in a ‘shift from commerce to science’
- PHE study finds people who have had COVID-19 can still transmit the virus
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- CureVac set to begin phase 3 COVID-19 vaccine study in healthcare workers
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
